par8o Launches Research Network
par8o has announced the launch of par8o Research Network (PRN), a clinical trial recruitment service that connects health center patients with nearby trials. To ensure both HIPAA and ethical compliance, par8o’s patient outreach and engagement protocol has been reviewed and approved by an independent Institutional Review Board, WCG IRB. With the launch of PRN, par8o will apply its knowledge to solve a major issue in clinical trials—specifically, the lack of racial, ethnic, and socioeconomic diversity.
“The lack of diversity in clinical research not only increases drug costs due to failed recruitment targets and delayed timelines, but also creates an ongoing legacy of healthcare injustice against minority groups,” said par8o CEO, Dr. Daniel Palestrant, MD. “It’s well known that different racial and ethnic groups can respond differently to the same treatments. Under-representation of minority groups in a clinical trial can create a legacy of bad data, which can ultimately impact patient access to therapeutics. We are confident that PRN will move the needle on the lack of diverse racial and ethnic representation in clinical trials.”
Read more in the full release,
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
- How the NIMBLE Study Supported Adherence With Quarterly Dosing of Cemdisiran
September 18th 2025
- Everything to Know About FDA’s Push Towards Radical Transparency in 2025
September 17th 2025
- IQVIA and Veeva Join Forces to Improve Efficiency and Patient Outcomes
September 17th 2025
- Managing Background Therapies in the NIMBLE Phase III Trial
September 17th 2025